LifeMD is trading 8.8% up now at $3.70 after management highlighted expected adjusted EBITDA profitability in the third quarter and stronger fourth-quarter revenue.

  • August 5 earnings showed $47.3 million of Q2 revenue and a $0.16 loss per share.
  • Management also sharply reduced 2026 guidance, while investors may be focusing on the projected recovery despite the reset.